# reload+after+2024-01-21 02:44:43.355643
address1§5858 Horton Street
address2§Suite 455
city§EmeryVille
state§CA
zip§94608
country§United States
phone§510 505 2680
website§https://www.4dmoleculartherapeutics.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform. It develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has product candidates that are in clinical trials, such as 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease cardiomyopathy. Its product candidates also include 4D-150 for the treatment of wet age-related macular degeneration and diabetic macular edema; and 4D-710 for the treatment of cystic fibrosis lung disease. In addition, the company has two product candidates that are in preclinical development stage, such as 4D-175 for the treatment of geographic atrophy; and 4D-725 for the treatment of alpha-1 antitrypsin deficiency lung disease. It has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.
fullTimeEmployees§144
companyOfficers§[{'maxAge': 1, 'name': 'Dr. John F. Milligan Ph.D.', 'age': 62, 'title': 'Executive Chairman', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 150000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David H. Kirn M.D.', 'age': 61, 'title': 'Co-Founder, CEO & Director', 'yearBorn': 1962, 'fiscalYear': 2022, 'totalPay': 920970, 'exercisedValue': 0, 'unexercisedValue': 200938}, {'maxAge': 1, 'name': 'Dr. Fariborz  Kamal Ph.D.', 'age': 60, 'title': 'President & COO', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 678401, 'exercisedValue': 0, 'unexercisedValue': 4158394}, {'maxAge': 1, 'name': 'Ms. Theresa  Janke', 'age': 48, 'title': 'Co-Founder & Chief of Staff', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 652315, 'exercisedValue': 0, 'unexercisedValue': 703125}, {'maxAge': 1, 'name': 'Mr. Uneek  Mehra', 'age': 51, 'title': 'Chief Financial & Business Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mike  Zanoni', 'title': 'VP of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Scott P. Bizily J.D., Ph.D.', 'age': 51, 'title': 'Chief Legal & Human Resources Officer and Corporate Secretary', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert Y. Kim M.B.A., M.D.', 'age': 62, 'title': 'Chief Medical Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. An  Song Ph.D.', 'title': 'Chief Development Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.', 'age': 62, 'title': 'Senior VP & Therapeutic Area Head of Pulmonology', 'yearBorn': 1961, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§2
boardRisk§6
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§2.636
priceToSalesTrailing12Months§38.089184
currency§USD
dateShortInterest§1702598400
forwardEps§-3.13
pegRatio§0.82
exchange§NMS
quoteType§EQUITY
shortName§4D Molecular Therapeutics, Inc.
longName§4D Molecular Therapeutics, Inc.
firstTradeDateEpochUtc§1607697000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3c71667a-4f1e-3d28-8cb0-26ab7aa9e925
gmtOffSetMilliseconds§-18000000
targetHighPrice§50.0
targetLowPrice§25.0
targetMeanPrice§33.56
targetMedianPrice§32.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§9
quickRatio§17.6
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
